Tlc Biopharmaceuticals, Inc.

Taiwan Liposome Company, Ltd.

Inspirmed Corp.

Wan-Ni Yu

Keelung Hong

Yun-Long Tseng

Sheue-Fang Shih

Hao-wen Kao

Yi-yu Lin

Hao-Wen Kao

Chun-yen Lai

Yi-Yu Lin

Jonathan Fang

Carl Oscar Brown

Min-Wen Kuo

Yu-Cheng Tseng

Ting-Yu Cheng

Jo-Hsin Tang

Tien-Tzu Tai

Hui-ting Wang

Weenee Yeun Ng Jao

Pei-hsien Hu

Provided is a pharmaceutical composition for use in treating postsurgical pain. The pharmaceutical composition comprises a lipid-based complex. The lipid-based complex comprises an amide-type anesthetic and at least one lipid, wherein a molar ratio of the amide-type anesthetic to the at least one lipid of the lipid-based complex is at least 0.5:1. The total amount of the amide-type anesthetic is at least 1.5 to 5 times of a standard therapeutic dose for treating postsurgical pain with the amide-type anesthetic to achieve an improved pain control with desired prolonged analgesic effect.

Pharmaceutical compositions for use in treating pain

Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more robust for large-scale manufacture and for providing a high molar ratio of local anesthetic agent to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Sustained-release anesthetic compositions and methods of preparation thereof

Provided is a liposomal sustained-release composition for use in treatment of pulmonary disease. The liposomal sustained release composition comprises a liposome that includes a polyethylene glycol (PEG)-modified lipid and encapsulates a tyrosine kinase inhibitor. Tyrosine kinase inhibitor is stably entrapped in the liposome, and the resulting liposomal drug formulation can be aerosolized or nebulized for administration via inhalation. This aerosolized liposomal drug formulation yields consistent pharmacokinetic and pharmacodynamic profiles while achieving desired efficacy and safety.

Inhalable liposomal sustained release composition for use in treating pulmonary diseases

Growing community of inventors

Taipei, Taiwan

Wan-Ni Yu